APOL1
Genotyping Is Incomplete without Testing for the Protective M1 Modifier p.N264K Variant
Glomerular Dis
.
2024 Feb 20;4(1):43-48.
doi: 10.1159/000537948.
eCollection 2024 Jan-Dec.
Authors
Rasheed Gbadegesin
1
,
Elena Martinelli
2
3
,
Yask Gupta
2
4
,
David J Friedman
5
6
,
Matthew G Sampson
6
7
8
9
,
Martin R Pollak
5
6
,
Simone Sanna-Cherchi
2
Affiliations
1
Division of Nephrology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
2
Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
3
Unità Operativa Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy.
4
Institute for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
5
Nephrology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
6
Harvard Medical School, Boston, MA, USA.
7
Division of Pediatric Nephrology, Boston Children's Hospital, Boston, MA, USA.
8
Kidney Disease Initiative and Medical and Population Genetics Program, Broad Institute, Boston, MA, USA.
9
Division of Nephrology, Brigham and Women's Hospital, Boston, MA, USA.
PMID:
38495868
PMCID:
PMC10942791
DOI:
10.1159/000537948
No abstract available
Keywords:
APOL1; Focal segmental glomerulosclerosis; Genetic modifier.
Grants and funding
R01 DK134347/DK/NIDDK NIH HHS/United States
R01 DK119380/DK/NIDDK NIH HHS/United States
UL1 TR001873/TR/NCATS NIH HHS/United States
R21 HD104176/HD/NICHD NIH HHS/United States
RC2 DK122397/DK/NIDDK NIH HHS/United States